TOP TEN perturbations for 39429_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39429_at
Selected probe(set): 203241_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39429_at (203241_at) across 6674 perturbations tested by GENEVESTIGATOR:
zalypsis study 2 / untreated OPM1 cell sample
Relative Expression (log2-ratio):-4.841793Number of Samples:2 / 2
Experimental | zalypsis study 2 |
OPM1 multiple myeloma cells treated in vitro with zalypsis (5 nM), a novel marine-derived compound with potent antimyeloma activity. Cells were harvested at the beginning of induction of cell death (15-20% cell death as assessed by Annexin V-FITC staining). ATC code:--- | |
Control | untreated OPM1 cell sample |
OPM1 multiple myeloma cells untreated. |
zalypsis study 1 / untreated MM1S cell sample
Relative Expression (log2-ratio):-2.9490595Number of Samples:2 / 2
Experimental | zalypsis study 1 |
MM1S multiple myeloma cells treated in vitro with zalypsis (5 nM), a novel marine-derived compound with potent antimyeloma activity. Cells were harvested at the beginning of induction of cell death (15-20% cell death as assessed by Annexin V-FITC staining). ATC code:--- | |
Control | untreated MM1S cell sample |
MM1S multiple myeloma cells untreated. |
endometrial cancer study 1 (PDX; carcinosarcoma, NOS; metastatic) / endometrial cancer study 1 (PDX; adenocarcinoma, NOS; metastatic)
Relative Expression (log2-ratio):-2.682414Number of Samples:3 / 2
Experimental | endometrial cancer study 1 (PDX; carcinosarcoma, NOS; metastatic) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary carcinosarcoma, NOS of the endometrium (subcutaneously implanted). Metastatic site of patient tumor sample is not reported. | |
Control | endometrial cancer study 1 (PDX; adenocarcinoma, NOS; metastatic) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary adenocarcinoma, NOS of the endometrium (subcutaneously implanted). Metastatic site of patient tumor sample is not reported. |
R547 study 1 (24h) / vehicle (DMSO) treated DU145 cell sample
Relative Expression (log2-ratio):-2.3695803Number of Samples:2 / 4
Experimental | R547 study 1 (24h) |
Human prostate carcinoma metastatic cell line DU145 treated with the CDK inhibitor R547 [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl]-(2, 3-difluoro-6-methoxyphenyl)methanone (Hoffmann-La Roche compound) for 24 hours at a 3xIC90 concentration of 5.1 μmol/L. ATC code:--- | |
Control | vehicle (DMSO) treated DU145 cell sample |
Human prostate carcinoma metastatic cell line DU145 treated with vehicle (DMSO) for 24 hours. |
dendritic cell study 6 (gardiquimod) / dendritic cell study 6 (untreated)
Relative Expression (log2-ratio):-2.2617788Number of Samples:7 / 8
Experimental | dendritic cell study 6 (gardiquimod) |
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+. | |
Control | dendritic cell study 6 (untreated) |
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+. |
kidney transplantation study 15 (8 week) / normal monocyte (CD14+) sample
Relative Expression (log2-ratio):-2.2063665Number of Samples:2 / 5
Experimental | kidney transplantation study 15 (8 week) |
CD14+ monocyte samples derived from kidney transplant patients 8 weeks post-transplantation. Samples were collected 8 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH). | |
Control | normal monocyte (CD14+) sample |
CD14+ monocyte samples derived from healthy control subjects. |
expO ovary cancer study 1 (transitional cell carcinoma, NOS; primary) / expO ovary cancer study 1 (clear cell adenocarcinoma, NOS; primary)
Relative Expression (log2-ratio):2.191596Number of Samples:2 / 12
Experimental | expO ovary cancer study 1 (transitional cell carcinoma, NOS; primary) |
Primary tumor tissue samples obtained from the ovary of patients with transitional cell carcinoma (NOS). | |
Control | expO ovary cancer study 1 (clear cell adenocarcinoma, NOS; primary) |
Primary tumor tissue samples obtained from the ovary of patients with clear cell adenocarcinoma (NOS). |
actinomycin D study 1 / mannitol treated A549 cell sample
Relative Expression (log2-ratio):-2.18256Number of Samples:3 / 3
Experimental | actinomycin D study 1 |
A549 human lung cancer cells were seeded eights days prior to treatment of non-cycling plateau phase cultures with drug. At four hours prior to RNA isolation, actinomycin D (5 ug/mL final concentration) was added to the culture. ATC code: | |
Control | mannitol treated A549 cell sample |
A549 human lung cancer cells were seeded eights days prior to treatment of non-cycling plateau phase cultures with drug. At four hours prior to RNA isolation, mannitol (5% final concentration) was added to the culture. |
bone cancer study 1 (PDX; chondroblastic osteosarcoma; primary) / bone cancer study 1 (PDX; myxoid chondrosarcoma; primary)
Relative Expression (log2-ratio):2.1729794Number of Samples:2 / 2
Experimental | bone cancer study 1 (PDX; chondroblastic osteosarcoma; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary chondroblastic osteosarcoma of the bone (subcutaneously implanted). | |
Control | bone cancer study 1 (PDX; myxoid chondrosarcoma; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary myxoid chondrosarcoma of the bone (subcutaneously implanted). |
connective/soft tissue cancer study 1 (PDX; connective and soft tissue, liposarcoma, NOS; primary) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, fibromyxosarcoma; primary)
Relative Expression (log2-ratio):-2.1463737Number of Samples:2 / 5
Experimental | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, liposarcoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, liposarcoma, NOS of the soft tissue (subcutaneously implanted). | |
Control | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, fibromyxosarcoma; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, fibromyxosarcoma of the soft tissue (subcutaneously implanted). |